In this manuscript, the authors use proteomics on genome-edited RBL-2H3-cells to identify protein targets for PKCB. They identify a novel phosphorylation site in VAMP8. Using substitution of four serines/threonines with glutamate or alanine, they reach the conclusion that phosphorylation of VAMP-8 blocks secretion, such that vesicles can dock, but not fuse. Strikingly, the phosphorylation motif is absent in eukaryotic neuronal VAMPs, but present in all other VAMPs.
The notion that phosphorylation within the interaction layers of SNAREs is used to regulate secretion is attractive and very interesting, and the manuscript is very well written. However, there are a couple of problems with the manuscript in its present form, which tempers my enthusiasm. It is unclear to me whether the authors can address these points, and it is hard to predict whether the additional experiments will support or refute the author's hypothesis.
Major points: 1. The basic conceptual problem of the paper is that while PKCB increases secretion, the phosphorylation of VAMP8 seems to decrease it. The authors interpret this as an 'incoherent feedforward loop', where PKCB both stimulates and inhibits secretion. This is a nice way to describe the data, but without any details about the positive leg of the loop -or the physiological conditions where one loop will win over the other -it is hard to feel satisfied about this. However, this is not the main point.
2. A large problem is that it is really not clear from the manuscript that the four residues T47, T53, S54, S61 are phosphorylated. The authors state that they identified two phosphopeptides, but they do not even include information about which of the four sites were actually phosphorylated in those peptides. Phosphorylation was also not demonstrated after physiological stimulation using standard methods (P32-incorporation (preferred), or phosphospecific antibodies after pulldown), with proper controls (mutation of the sites one-by-one to identify the phosphorylated amino acids). Without such a demonstration, it is hard to accept the premise of the paper. These data should be included. Preferably phosphorylation should be assessed quantitatively, so that the mol-% of phosphate incorporation is measured.
3. It is claimed based on glutamate substitutions that phosphorylation of VAMP8 inhibits secretion (Fig. 3) . However, this experiment is not evidence that the sites are actually phosphorylated, or that phosphorylation inhibits secretion. It cannot be assumed without proof that glutamate substitutions are phosphomimetic. This might or might not be the case. It would be necessary to demonstrate that the glutamate substitutions result in an in vitro function similar to the phosphoresidues, or that the effects of glutamate substitutions and PKCB activation occlude each other in a cellular context. The latter is admittedly hard when the effect of global PKCB activation is the opposite of the effect of the glutamate substitutions, but this is exactly the reason that the reader can raise doubt about whether these mutations are phosphomimetic.
4. The threonines and serines that are mutated here often participate in H-bonds, which stabilize the SNARE-complex. The biochemical consequences of charge or alanine substitutions are hard to predict. Therefore, it is unsatisfying that no biochemical data have been included to demonstrate whether basic SNARE-complex formation is compromised by glutamate or alanine substitutions. I guess the authors imply that the glutamate substitutions would hinder SNARE-complex formation, but it would be better to show this directly.
5. The conclusion that phosphorylation blocks secretion but not docking (Fig. 4) , is not entirely convincing. First, the expression level of the VAMP8, VAMP8Ala and VAMP8Glu must be quantified. It is surprising that the VAMP8Glu has so many more puncta at the membrane, but this could be because of a higher expression level. Second, the number of puncta runs counters to the secretion level. Could this be because high secretion depletes the vesicles at the plasma membrane, and low secretion cause accumulation? In that case, the different number of puncta would not reflect docking, but fusion. Live-cell imaging would probably be required to make the distinction.
Referee #2:
In this study, the authors have identified a regulatory phosphorylation site in the SNARE motif of the R-SNARE VAMP-8 and show that this site is inhibitory for exocytotic fusion. Using a cell line model for mast cell degranulation the authors first show that inhibition of protein kinase C reduces exocytosis. They then knocked out two isoforms of PKC, again resulting in a reduction of stimulusdependent release that was rescued by transfection with wildtype PKC variants. Comparing wildtype and knockout cell lines the authors then carried out a phosphoproteome screen and identified, among many other phosphopeptides, four peptides corresponding to the SNARE VAMP8, two of which corresponding to serine residues that are partially buried when mapped on the structure of a VAMP8-containing SNARE complex. Using a database screen the authors then found out that these serines are highly conserved among many R-SNAREs across many species, with the conspicuous exception of those operating in neuronal exocytosis. The authors then used complementary approaches to show that phosphorylation of these sites is inhibitory. These approaches included a lipid mixing assay using liposomes reconstituted with phosphomimetic variants of VAMP8. They then studied secretion in VAMP8 knockdown cells transfected with serine mutation of VAMP8 in which one or several of the serines were replaced either with glutamate (phosphomimetic) or alanine (cannot be phosphorylated), with the phosphomimetic mutants not being able to rescue VAMP8 knockdown whereas the alanine mutants resulted in secretion that was even higher than in the wildtype. Finally they used TIRF imaging to localize VAMP8 near the plasma membrane and found that VAMP8 positive particles were increased in the phosphomimetic mutants, which was interpreted as an increased amount of docked vesicles.
All in all this is a highly interesting and elegant study, carried out by two top-class laboratories, with significant novelty both for the field of mast cell signaling and for the SNARE field. Thus, I strongly recommend publication in EMBO Journal. There are only few minor issues that I noted during reading and that the authors may consider:
1. In the bulk liposome fusion assay, the SNARE:lipid ratio was very high, which may explain why some fusion remained with the phosphomimetic mutant. Moreover, the concentration of sulphorhodamine is given as 50 nM, which appears rather low -please check. In any case, it is more meaningful to note the percentage of labeled vs. unlabeled lipid which is the relevant parameter for self-quenching. This paper describes an interesting study reporting phosphorylation of the SNARE motif of VAMP8 (putatively by PKCB) and suggesting that such phosphorylation impairs secretion. Conceptually, the most interesting aspect of the paper is that the phosphorylated residues are in the apolar layers with buried side chains in the helix of the SNARE complex. Correspondingly, phosphorylation is expected to impair SNARE complex formation and hence secretion. The authors provide supporting evidence for this notion using in vitro reconstitution assays and cellular secretion assays. Overall, I believe that the paper will be of interest to the wide audience of EMBO Journal, but there are a number of concerns that need to be addressed before publication.
1. It is surprising that, at the end of the introduction (top of page 2), the authors state that posttranslational regulation of SNARE domains has not yet been reported, as there is abundant literature on phosphorylation of SNAP-25 at a SNARE domain (e.g. Shu et al. J. Neuroscience 2008 just to mention one paper). From my not exhaustive knowledge of the literature, what I believe is novel is the notion that a buried residue is phosphorylated, which is what makes this paper interesting, but in any case it is imperative that the authors do an extensive analysis of the literature and properly cite key relevant precedents on this subject.
2. The authors make a strong claim that PCB phosphorylates VAMP8 and all VAMPs except the neuronal ones, where the corresponding residues are conserved, and that such phosphorylation abolishes membrane fusion (or 'terminates' in the title of the paper). However, I believe that they should tone down these conclusions unless they can provide more definitive data. They do provide evidence for phosphorylation of VAMP8 by PKCB and they show that replacing the phosphorylated residues with glutamates abrogates the ability of VAMP8 to rescue the secretion defects caused by siVAMP8. However, the mentioned defects are rather small (they seem to be about 35% in Fig. 4A ) and hence it is difficult to be convinced with these data that the mutations really abolish fusion. Note also that the replacement with phosphomimetic residues supports the idea that phosphorylation inhibits fusion, but it does not tell anything about the extent to which phosphorylation occurs in vivo and which kinase phosphorylates those residues. Moreover, if I understand Table S1 correctly, it appears that phosphorylated peptides identified by proteomics correspond to only two of the four residues that are purportedly phosphorylated. Note also that the strong conclusion of the title is not supported by the reconstitution data (see next point).
3. The reconstitution results of Fig. 3 suggest that replacement of three of the putatively phosphorylated residues of VAMP8 with glutamates (all of which are at the C-terminal half of the SNARE complex) impairs but does not abolish liposome fusion. This is a surprising result because the mutations are expected to strongly hinder or probably completely abolish C-terminal zippering of the SNARE complex, which would imply that such zippering is not essential for membrane fusion. Moreover, these results contradict the strong statement made in the title of the paper. Response: The reviewer brings up an important point. We would like to first argue that the molecular mechanism of how PKC is involved in secretion has not been resolved yet, even though it has been studied for over three decades (Nishizuka, 1986) with nearly all studies focusing on putative positive PKC-mediated regulatory mechanism that dominate the initial response. Nevertheless, PKC-mediated secretion is incomplete with many secretory vesicles remaining in the cell which has long argued that a mechanism must exist that restricts secretion. We believe that our study is the first addressing a molecular mechanism by which the same PKC that mediates secretion can also restrict secretion. Given the ubiquitous nature and relevance of the regulation of secretion this is of broad interest. In mast cells the main PKC isozyme is PKCB and we have therefore concentrated on this isoform (RNA-seq HMC-1 cells, www.proteinatlas.org (Uhlén et al, 2015)). Furthermore, our study will likely be useful for future studies focusing on positive regulators as we identify several plausible targets. In Appendix  Table S1 we present a complete list of the putative PKCB substrates we identified that may be part of the positive leg of the incoherent feed-forward loop. However, in this manuscript we focus on the novel inhibitory role of PKCB mediated by VAMP8 phosphorylation.
2) Comment: A large problem is that it is really not clear from the manuscript that the four residues T47, T53, S54, S61 are phosphorylated. The authors state that they identified two phosphopeptides, but they do not even include information about which of the four sites were actually phosphorylated in those peptides.
Response: The reviewer raises an important point and we apologize for not being more clear. We have added a new figure ( Figure EV2C ) to clarify which phosphorylation sites that we identified in VAMP8. Our phosphoproteomics approach detected 4 different phosphopeptides from VAMP8: T47, T53, S54 and S17 (S17 is not conserved in mammals and was hence not further investigated). As shown in Figure EV2C , all peptides identified for VAMP8 contained a single phosphorylated residue and were observed under physiological conditions with antigen stimulation. Other VAMP8 phosphopeptides may also be present, such as double or triple phosphorylations, but we failed to detect such phosphopeptides in our analysis. The potential phosphorylation site S61 was not identified in our phosphoproteomics experiments, but the residue was found to be evolutionary conserved ( Figure 2E ) and has previously been reported to be phosphorylated (www.phosphosite.org (Hornbeck et al, 2015) ). Hence, the mutant S61E was only used in Figure 4B as a single phosphomimetic mutation. All other mutations were focused on residues T47, T53 and S54, which were identified as phosphorylated in our RBL cell phosphoproteomics experiments.
Comment: Phosphorylation was also not demonstrated after physiological stimulation using standard methods (P32-incorporation (preferred), or phosphospecific antibodies after pulldown), with proper controls (mutation of the sites one-by-one to identify the phosphorylated amino acids). Without such a demonstration, it is hard to accept the premise of the paper. These data should be included. Preferably phosphorylation should be assessed quantitatively, so that the mol-% of phosphate incorporation is measured.
Response: Similar to the previous point, we argue that we have identified the three sites (T47, T53, S54) as phosphorylated sites under physiological conditions with our phosphoproteomics approach. In addition, there are to date 77 reports (T47: 46 reports, T53: 24 reports, S54: 7 reports), available in proteomics databases, that these three sites can be phosphorylated. These studies were deposited by others without focusing on these specific sites (www.phosphosite.org (Hornbeck et al, 2015) ).
However, in response to the referee we have attempted alternative methods to detect the same phosphorylation events but were not able to detect the VAMP8 phosphorylation as a shifted band on SDS-PAGE. We were expecting to observe a shift upon phosphorylation since VAMP8Glu (T47E, T53E, S54E) runs slower than wild type VAMP8 ( Figure EV5C and E). There are three plausible reasons for this observation:
(1) There might be typically only a single site phosphorylated and we may miss single site events in the shift assay. (2) VAMP8 phosphorylation competes with vesicle fusion, but the phosphorylation may have a short lifetime before being reversed by phosphatases but can nevertheless oppose secretion during this time window. (3) Intracellular VAMP8 that is not localized at the plasma membrane will not be phosphorylated. Only the fraction of VAMP8 situated close to the plasma membrane, co-localized with active PKC, can be phosphorylated and thus inhibited.
The main point to consider is that PKCB is exclusively activated at the plasma membrane requiring Ca 2+ signals, diacylglycerol and also PIP 2 lipids, while most of the VAMP8 at any given time is internally associated with vesicles. Secretion occurs during a ~20 minute time window with individual fusion events lasting less than a second. Furthermore, our data shows that cells expressing VAMP8Ala, which avoids phosphorylations altogether, have increased secretion compare to wild type VAMP8. We now added new data showing that this is the case when the mutant is expressed at the same level as wildtype ( Figure EV5E ). Finally, our glutamic acid mutation studies with TIRF microscopy suggest that phosphorylated VAMP8 will arrest at a late step in the fusion response after docking. If most VAMP8 were to be phosphorylated, we should observe more docked vesicles. Nevertheless, this consideration suggests that many of the visible docked vesicles that we also observe in wildtype VAMP8 cells during secretion may reflect a fraction of docked vesicles that are prevented from fusion due to phosphorylation. We have now added a sentence to the discussion to elucidate these points.
3) Comment: It is claimed based on glutamate substitutions that phosphorylation of VAMP8
inhibits secretion (Fig. 3) Response: We agree with the statements of the referee that glutamic acid substitution is an imperfect model for serine/threonine phosphorylation but has however led to important new insights in a large number of studies. Nevertheless, we would like to point out that we also show that expression of VAMP8Ala increases secretion as compared to expression of wild type VAMP8 ( Figure 4A ). The gain of function of VAMP8Ala, in combination with the loss function of VAMP8Glu, provides complementary support that phosphorylation of wild type VAMP8 inhibits secretion and also that phosphorylation has a physiological significant role in reducing secretion. We have now also added new data ( Figure EV5E ) which demonstrate that VAMP8, VAMP8Ala and VAMP8Glu are expressed at similar levels in these experiments. Response: In response to this valid point, we have added new data in Figure EV5C . The results are consistent with the hypothesis that VAMP8 and VAMP8Ala form similar complexes and VAMP8Glu is less efficient. SDS-resistant SNARE-complexes is observed for all three VAMP8 proteins (VAMP8, VAMP8Ala and VAMP8Glu) and the complexes are dissociated after boiling. There are no visible differences between VAMP8 and VAMP8Ala, however VAMP8Glu is different, unassociated STX3 is observed in the non-boiled sample (absent in non-boiled VAMP8 and VAMP8Ala). Also higher order complexes were formed in VAMP8 and VAMP8Ala, which are absent in VAMP8Glu. Moreover, the alanine substitution is unlikely to have an effect on the SNARE-complex formation, since in our evolutionary comparison of 3,790 eukaryotic sequences of v-SNAREs showed that alanine substitutions have occurred naturally in a large subclass of neuronal VAMPs during evolution for several of the v-SNAREs ( Figure 2E ). Response: As suggested by the referee, we have added new data ( Figure EV5E ) showing protein expression levels of VAMP8. We show similar expression levels of overexpressed VAMP8, VAMP8Ala and VAMP8Glu. Furthermore, VAMP8 overexpression levels are similar to endogenous VAMP8 expression levels. Also, siRNA for VAMP8 efficiently knocks down protein expression. This shows that the increase of puncta at the membrane is not due to higher expression levels of VAMP8Glu. As the referee points out, there may also be a contribution to the membrane vesicle pool due to the fact that fewer vesicles have fused when VAMP8Glu is expressed.
Referee #2: 1) Comment: In the bulk liposome fusion assay, the SNARE:lipid ratio was very high, which may explain why some fusion remained with the phosphomimetic mutant.
Response: The referee is making a valid point. As suggested by the referee, we have added new data where the protein/lipid ratio is decreased from 1:200 to 1:500 in the content-mixing assay ( Figure 3B ). At this lower protein concentration, we observed content-mixing using wild type VAMP8, which was suppressed by VAMP8Glu, however some activity still remained with VAMP8Glu at 1:500 protein/lipid ratio.
Comment: Moreover, the concentration of sulphorhodamine is given as 50 nM, which appears rather low -please check. In any case, it is more meaningful to note the percentage of labeled vs. unlabeled lipid which is the relevant parameter for self-quenching.
Response: We thank the referee for noticing that we had an incorrect sulforhodamine dye concentration, which has now been corrected to 50 mM. As suggested by the referee, we have added this sentence to the Materials and Methods: "Protein-reconstituted t-and v-SNARE proteoliposomes were mixed at a molar ratio of 1:1, both at 0.1 mM lipid concentration."
2) Comment: The authors claim that this is the first report of a regulatory phosphorylation within a SNARE protein. According to my knowledge, this is not entirely correct (see e.g. Polgar et al., (2003) JBC 278, 44369, Nagy et al. (2002) J. Neurosci. 22, 9278).
Response: We have added the references suggested by the referee. Together with the references cited by referee #3, these studies focused to our knowledge on outside phosphorylation sites involved mostly in positive regulation of secretion but not on the type of internal phosphorylation we report here that interfere with SNARE complex formation. We now discuss more clearly the novelty in our study of how phosphorylation inside the SNARE-domain can suppresses fusion.
Referee #3: 1) Comment: It is surprising that, at the end of the introduction (top of page 2), the authors state that posttranslational regulation of SNARE domains has not yet been reported, as there is abundant literature on phosphorylation of SNAP-25 at a SNARE domain (e.g. Shu et al. J. Neuroscience 2008 just to mention one paper).
Response: As pointed out in our response to reviewer #2, we have added the references suggested by the referee and discuss the differences between the two types of phosphorylation sites.
2) Comment: The authors make a strong claim that PKCB phosphorylates VAMP8 and all VAMPs except the neuronal ones, where the corresponding residues are conserved, and that such phosphorylation abolishes membrane fusion (or 'terminates' in the title of the paper). However, I believe that they should tone down these conclusions unless they can provide more definitive data. They do provide evidence for phosphorylation of VAMP8 by PKCB and they show that
replacing the phosphorylated residues with glutamates abrogates the ability of VAMP8 to rescue the secretion defects caused by siVAMP8. However, the mentioned defects are rather small (they seem to be about 35% in Fig. 4A ) and hence it is difficult to be convinced with these data that the mutations really abolish fusion.
Response: We agree with the point raised by the referee. As stated by the referee, VAMP8Glu fails to rescue the secretion defects caused by siVAMP8, but does not act as dominant negative to abolish all secretion in cells. We would only like to add that we cannot express VAMP8Glu to much higher levels than is endogenously expressed which makes it difficult to test whether there could be a potential dominant negative effect at much higher levels. Nevertheless, the studies are best consistent with the interpretation that phosphorylation of VAMP8 prevents VAMP8 from participating in successful fusion events, rendering it non-functional. As suggested by the referee we have toned done the language throughout the text and changed the title from "terminates" to "suppresses".
Comment: Note also that the replacement with phosphomimetic residues supports the idea that phosphorylation inhibits fusion, but it does not tell anything about the extent to which phosphorylation occurs in vivo and which kinase phosphorylates those residues.
Response: The referee makes a valid point. However, we would like to emphasize that we show that expression of VAMP8Ala increases secretion as compared to expression of wild type VAMP8 ( Figure 4A ). The gain of function of VAMP8Ala, in combination with the loss function of VAMP8Glu, and the fact that VAMP8 phosphorylation was detected in our proteomic experiments, argues that phosphorylation of wild type VAMP8 inhibits secretion under physiological conditions and that this is dependent on PKC activity albeit we cannot definitely proof that the phosphorylation is direct. Note also that expression levels are similar of all VAMP8 constructs as shown in Figure EV5E , which was added to the revised manuscript. Table S1 correctly, it appears that phosphorylated peptides identified by proteomics correspond to only two of the four residues that are purportedly phosphorylated.
Comment: Moreover, if I understand
Response: We apologize for not being more clear. We have added a new figure ( Figure EV2C ) to clarify which phosphorylation sites that we identified in VAMP8. Our phosphoproteomics approach identified 4 different phosphopeptides from VAMP8: T47, T53, S54 (S17, is not conserved in mammals and was hence not further investigated). The potential phosphorylation site S61 was not observe in our phosphoproteomics dataset, but the residue was found to be evolutionary conserved ( Figure 2E ) and has previously been reported to be phosphorylated (www.phosphosite.org (Hornbeck et al, 2015) ). Hence, the mutant S61E was only used in Figure  4B as a single phosphomimetic mutation. All other mutations were focused on residues T47, T53 and S54, which were identified as phosphorylated in our phosphoproteomics experiments.
3) Comment: The reconstitution results of Fig. 3 Response: We agree with the referee that it would be reasonable to assume that VAMP8Glu would abolish liposome fusion (Figure 3) . However, there is nevertheless much less liposome fusion with VAMP8Glu compared to wild type VAMP8. Our data argues that the decreased liposome fusion efficiency observed with VAMP8Glu translates into a much bigger loss of function of secretion involving VAMP8Glu in living cells, where the lipid composition and protein environment are different. We have added new data on SNARE-complex formation ( Figure EV5C ), which shows that VAMP8Glu can form an SDS-resistant SNARE-complex, but less efficient compared to VAMP8 and VAMP8Ala, suggesting that formation of a partially zippered complex might suffice in vitro an result in some fusion while the same partial zippering cannot mediate fusion in living cells.
4) Comment: It is hard to read the text of Fig. 2. All figures should be made clearly readable in a printed format. 2nd Editorial Decision 31 May 2016
Thank you for submitting your revised manuscript for our consideration. Your manuscript has now been seen once more by two of the original referees (see comments below), and I am happy to inform you that they are both broadly in favor of publication, pending satisfactory minor revision.
I would therefore like to ask you to address the remaining concerns and to provide a final version of your manuscript. We also need a conflict of interest statement in the manuscript text.
-
In their revised paper Malmersjö et al. have added new experimental data and clarified a number of points, for instance which phosphopeptides they actually detected, and expression levels of their constructs. There are still basic shortcomings, especially the inability to detect phosphorylation of these residues in living cells. The authors argue that this might be because phosphorylation events only take place at the membrane and is short lived. This is possible, but it is hard to accept that this would not be detectable at all, even when using phosphatase inhibitors. However, at this stage I think it is fair to accept the paper and make it available to the scientific community. The basal finding/hypothesis that phosphorylation inside the SNARE-domain can negatively regulate secretion is interesting and potentially important, and the paper has been improved in revision.
Referee #3:
The authors have largely addressed most of my concerns, but I do have two comments.
1. I appreciate the effort the authors have made to tone down the conclusions, but I still worry about sentences such as 'VAMP8 phosphorylation suppresses vesicle fusion in vitro and secretion in living cells' (abstract). While I think that the data reported in the paper are suggestive of this conclusion, will be of interest to a wide audience and should be published, I do not think that the conclusion expressed in this sentence has been really demonstrated. Note in particular the responses from the authors to the concerns of reviewer 1, which are valid responses but at the same time emphasize the difficulty of fully proving this conclusion. Hence, wouldn't it be better to tell the reader something like 'Our data suggest that ...', rather than making such a definitive statement?
2. The liposome fusion results remain a concern because the effect of the glutamate mutations is much more limited than expected, the content mixing curves are far from saturation and there is some content mixing even in the 'No protein' control. This is not a trivial issue, since the data as presented leads to a very important conclusion for the field of membrane fusion, i.e. that fusion can proceed even if a large section of the C-terminus of the SNARE complex does not zipper (and at about 50% efficiency compared to WT!). To reach such an important conclusion, data of considerably higher quality would be desirable. I suggest three possibilities to address this issue: i) the authors make a strong effort to improve the quality of the data, optimizing multiple variables as is common in these assays; ii) the reconstitution data are removed; or iii) the current data are kept in the paper, but the authors make a clear statement that these data are surprising and a much more thorough study will be required before concluding that zippering of the C-terminal half of the SNARE complex is not required for fusion. Response: We thank the referee for the comments. We apologize that the discussion of our results came across as misleading. Indeed, our data does not uniquely support that a half zippered SNAREcomplex is sufficient for the observed relatively slow fusion to occur and we have now removed any such speculation from the text.
We demonstrate that VAMP8Glu can form an SDS-resistant SNARE-complex, but less efficiently compared to wild type VAMP8 (Fig. EV5C) . The qualitative nature of such gel-based experiments is supported by our bulk liposome fusion experiments that show that the kinetics of the SNAREmediated fusion is slower for VAMP8Glu as compared to wild type VAMP8 (Fig 3B) . We suggest that the slower fusion kinetics prevents VAMP8Glu from rescuing the siVAMP8 effect on secretion in living cells (Fig 4A) . The small amount of content mixing observed with the 'No protein' control (black line in Fig 3B) is likely due to leakage in this bulk fusion assay. We have added this explanation to the figure caption and changed the name of the control to 'leakage'. Thank you for sending the revised version of your manuscript to us. I appreciate the introduced changes, and I am happy to accept your manuscript for publication in The EMBO Journal. Do the data meet the assumptions of the tests (e.g., normal distribution)? Describe any methods used to assess it.
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